Suliman Alsagaby

Dr. Suliman Alsagaby

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2019 in Artificial Cells, Nanomedicine, and Biotechnology
Verified
Journal Article
Open access
YKYang Ke
Yang Ke
MAMohammed Saleh Al Aboody
Mohammed Saleh Al Aboody
WAWael Alturaiki
Wael Alturaiki
SASuliman Alsagaby
Suliman Alsagaby
FAFaiz Abdulaziz Alfaiz
Faiz Abdulaziz Alfaiz
SMSuresh Mickymaray
Suresh Mickymaray
Bionanotechnology has pivotal role in the development of a novel therapy, applications of gold nanoparticles (AuNPs) in the treatment of cancer. In this study, we found that therapeutics, pharmaceutics and diagnostic effectiveness of photosynthesized Catharanthus roseus (CR) AuNPs induces mitochondrial-mediated apoptotic signalling pathways via reactive oxygen species (ROS) induced cytotoxicity in cervical cancer cell line (HeLa) by in vitro model. The present examinations were for the most part centred around the gold chloride and photosynthesis AuNPs from the fluid leaf concentrate of CR and their harmful impacts on HeLa cell lines. The synthesized AuNPs were characterized using numerous biophysical analyses such as UV-vis, DLS, EDX, HR-TEM, SAED, FTIR and AFM. The synthesized AuNPs in the particle size range of 25–35 nm was confirmed by HR-TEM. The element gold and the crystalline nature of AuNPs were finalized using EDX, respectively. Anticancer potential of CR-AuNPs was studied using HeLa cells and the cytotoxic mechanism has been evaluated using MTT, mitochondrial-mediated apoptotic pathway through AO/EtBr staining assay, pro-apoptotic (Bax), anti-apoptotic (Bcl-2 and Bid) protein expression western blotting analysis and caspases activity using ELISA analysis. In in vitro study, the IC50 of HeLa cells was found to be 5 µg/ml confirmed using MTT assay. The present data revealed that drug delivery vehicles developed on CR-AuNPs nanocomplexes might include extensive purpose in human cancer diagnosis and treatment.

20 July 2023 in International Journal of Food Properties
Verified
Journal Article
Open access
ZMZarina Mushtaq
Zarina Mushtaq
NSNabeelah Bibi Sadeer
Nabeelah Bibi Sadeer
Muzzamal HussainMuzzamal Hussain
Muzzamal Hussain
MAMahwish
Mahwish
SASuliman Alsagaby
Suliman Alsagaby
MMMohamad Fawzi Mahomoodally
Mohamad Fawzi Mahomoodally

1 December 2015 in IET Nanobiotechnology
Verified
Journal Article
Open access
PDF file
KGKasivelu Govindaraju
Kasivelu Govindaraju
KKKarthikeyan Krishnamoorthy
Karthikeyan Krishnamoorthy
SASuliman Alsagaby
Suliman Alsagaby
GSGanesan Singaravelu
Ganesan Singaravelu
MPMariappan Premanathan
Mariappan Premanathan
Therapeutic applications of nanoparticles (NPs) are rapidly increasing for their utility in medicine, especially cancer therapy. The present study investigated the green synthesis of silver NPs (Ag NPs) of 10 nm size using Sargassum vulgare and its preferential ability to kill cancerous human myeloblastic leukemic cells HL60 and cervical cancer cells HeLa as compared with normal peripheral blood mononuclear cells. DNA fragmentation study and annexin V marker fluorescence‐activated cell sorting (FACS) analysis revealed the Ag NP‐induced cell death is through apoptosis. Transmission electron micrographs have showed the endocytosis of Ag NPs into the nucleus. Ag NPs inhibited the lipid peroxidation‐induced reactive oxygen species generation, thus preventing the irradiation‐related carcinogenesis. This study suggested that a mechanism underlying the toxicity of Ag NPs towards cancer cells is due to DNA damage and apoptosis. The authors’ findings revealed the potential utility of as‐prepared Ag NPs in the treatment of cancer as prophylactic agent with antioxidant property and chemotherapeutic agent for their selective toxicity to cancer cells.

1 November 2018 in Journal of Infection and Public Health
Verified
Journal Article
Open access
RVRajendran Vijayakumar
Rajendran Vijayakumar
TSTimothy Sandle
Timothy Sandle
MAMohammad S. Al-Aboody
Mohammad S. Al-Aboody
MAMeshal K. AlFonaisan
Meshal K. AlFonaisan
WAWael Alturaiki
Wael Alturaiki
SASuliman Alsagaby
Suliman Alsagaby
The aim of this study was to determine the frequency of biocide resistant genes, qacA, qacE and cepA in multidrug resistant (MDR) bacteria: Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii and to correlate the presence or absence of resistant genes with biocides susceptibility. The study included 44 MDR K. pneumoniae, P. aeruginosa and A. baumannii microorganisms. The bacteria were screened for the presence of biocide resistant genes by the polymerase chain reaction (PCR) method. The test organisms were isolated from various clinical specimens in the Qassim region, Saudi Arabia. The in vitro susceptibility tests of the three biocides (benzalkonium chloride, cetrimide and chlorhexidine gluconate) were studied against the test isolates by broth microdilution method following Clinical and Laboratory Standards Institute guidelines. With the distribution of biocide resistant genes in K. pneumoniae, all 9 isolates (100%) possessed cepA; 4 (44.4%) and 1 (11.1%) isolate contained qacA and qacE genes respectively. Among 24 isolates of A. baumannii tested, cepA, qacA and qacE genes were found in 54.2%, 16.7% and 33.3% of isolates respectively. Among 11 P. aeruginosa isolates, 63.6% contained cepA gene, 18.2% contained qacE genes, and none of the isolates harboured qacA gene. There was no significant correlation between presence or absence of biocide resistant genes and high MIC values of the test isolates (p≥0.2). Our observations imply that there was no significant correlation between presence or absence of biocide resistant genes and MICs observed in MDR K. pneumoniae, P. aeruginosa and A. baumannii. Further studies are required to find to confirm the trend of reduced susceptibility to biocides of problematic nosocomial pathogens.

9 July 2024 in Food Science & Nutrition
Verified
Journal Article
Open access
MSMuhammad Shahbaz
Muhammad Shahbaz
HNHammad Naeem
Hammad Naeem
MBMaryam Batool
Maryam Batool
MIMuhammad Imran
Muhammad Imran
Muzzamal HussainMuzzamal Hussain
Muzzamal Hussain
EJEntessar Al Jbawi
Entessar Al Jbawi
Moringa oleifera, a widely recognized plant more commonly known as moringa, has obtained significant research interest in recent years due to its prospective physiological advantages, including its claimed ability to counteract carcinogenesis. The moringa plant has been found to possess bioactive components that exhibit promising anticancer activities against different human cancers, such as breast cancer, prostate cancer, pancreatic cancer, etc. The cytotoxic properties of moringa seed extracts on cancerous cells have also been provided in this paper along with other notable health benefits. The extracts derived from moringa seeds inhibit cancer proliferation and promote cancer cell apoptosis through multiple signaling pathways. They also stimulated intracellular reactive oxygen species (ROS) production and subsequently induced caspase‐3 activity. The impact of moringin and avenanthramide 2f on the stimulation of caspases 2, 4, 8, and 9 results in reduction in the proliferation of cancer cells. The results reported by research studies hold significant implications for identifying and targeting specific molecular entities that could serve as potential therapeutic targets in search of effective cancer treatments. Furthermore, the flavonoids in moringa seed can remove mitochondrial reactive oxygen species, protecting beta cells and bringing hyperglycemia under control. M. oleifera seed oil can reduce the risk of cardiovascular diseases via reduced malondialdehyde (MDA) formation and modulation of cardiac superoxide dismutase (SOD) and glutathione peroxidase (GPx) activity. This article provides a comprehensive summary of the noteworthy discoveries derived from a rigorous investigation that explored into the impact of moringa seeds on the prevention/reduction of various cancers and other complex diseases.

8 December 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MKMostafa M. Khodeir
Mostafa M. Khodeir
HSHassan A. Shabana
Hassan A. Shabana
ZRZafar Rasheed
Zafar Rasheed
AAAbdullah S. Alkhamiss
Abdullah S. Alkhamiss
MAMohammad S. Alkhowailed
Mohammad S. Alkhowailed
WAWaleed Al Abdulmonem
Waleed Al Abdulmonem
Background: After recovery from acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many patients experience long-term symptoms in different body systems. The aim of the present study was to identify these symptoms, their severity, and their duration as a first step in building a system to classify post-recovery long-term symptoms of coronavirus disease 2019 (COVID-19). Methods: An online-based cross-sectional survey was administered between September and October 2020. Data regarding the severity of post-recovery symptoms and their duration were collected using an Arabic questionnaire divided into six categories encompassing the 20 most prevalent symptoms. Results: A total of 979 patients recovered from COVID-19 in Saudi Arabia in the study period, of whom 53% were male and 47% were female. The most common symptoms included general fatigue and weakness (73% each), with moderate severity of neurological symptoms including mood changes (41%) and insomnia (39%). Among the special senses, loss of smell and taste of marked severity were reported by 64% and 55% among respiratory symptoms, cough of mild severity (47%), and dyspnea of moderate severity (43%). Loss of appetite of moderate severity was reported in 42%, and diarrhea, abdominal pain, and nausea of mild severity were reported by 53%, 50%, and 44% of respondents, respectively. Conclusions: Long-term symptoms after recovery from COVID-19 warrant patient follow-up. The authors propose a classification system as a starting point to guide the identification and follow-up of long-term symptoms post-recovery, and recommend larger-scale studies to broaden the definition of recovery from COVID-19, which appears to have two phases, acute and chronic.